TScan Therapeutics, Inc. Common Stock Stock Prediction
AI-powered sentiment analysis and prediction trends for TCRX, updated each market day.
TCRX AI Sentiment
AI sees no strong directional signal for TScan Therapeutics, Inc. Common Stock stock over the next 10 market days.
Prediction date: April 10, 2026
Subscribers see precise scores, buy/sell targets, and full analytics.
About TScan Therapeutics, Inc. Common Stock
TScan Therapeutics Inc is a fully integrated clinical-stage biotechnology company focused on developing a robust pipeline of T cell receptor (TCR)-engineered T cell, or TCR-T, therapies for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.
Sector
Exchange
Market Cap
$60,315,720
Cap Tier
Employees
142
Headquarters
WALTHAM, MA
Listed Since
July 16, 2021
Website
TCRX Sentiment Trend — Last 30 Predictions
Sentiment zones: Bullish · Neutral · Bearish
TCRX Volatility
TScan Therapeutics, Inc. Common Stock has shown high price volatility over the last 5 trading days. High volatility means larger price swings — this can present both opportunity and risk for traders.
